Fight chronic kidney disease with “Care, Know and Detect”

In 2017, chronic kidney disease (CKD) was the 4th leading cause of premature death in the Philippines, with kidney failure being the 9th leading cause of death and disability.

In 2021, the hemodialysis procedure exceeded the procedure cases reimbursed by the Philippine Health Insurance Corp.

Dr Nickson Austria, nephrologist, said: “As the burden of CKD falls more heavily on the shoulders of patients, it is essential to have these patient-centred initiatives.”

“We cannot do this alone. It is a collective effort of the medical community, patients, government and private sectors to be able to improve the overall quality of life of Filipinos and save more patients,” said Dr. Austria.


TO celebrate National Kidney Month, AstraZeneca Philippines and MedAsia Medical Products Corporation have signed an agreement to expand the country’s access to automated tests that can aid in the early detection of CKD.

“By working in partnership throughout the patient care journey, I hope we can tangibly improve outcomes for CKD patients and support our healthcare systems for many years to come,” said Jo. Feng, senior vice president of AstraZeneca Asia Area.

The partnership between AstraZeneca Philippines and Medasia will allow more Filipino patients to have access to urine albumin to creatinine ratio (uACR) devices, which detect the amount of a small protein called albumin present in urine, one of the first indicators of kidney failure. sickness.

Tests can be done in doctor’s offices, hospitals or diagnostic clinics.

Simple urine test

DEPENDING on the patient’s history and existing health conditions, the uACR is a simple urine test that can be done once a year. Only a small amount of urine is needed (about two tablespoons) to perform the test, which will then be checked by the uACR machine.

A normal amount of albumin in urine is less than 30 mg/g. Anything above 30 mg/g can be an indication of CKD.

“CKD is grossly underdiagnosed. Now that our uACR machines are more accessible to patients, we are committed to helping AstraZeneca Philippines and the medical community get to the root of the problem,” said MedAsia CEO Oliver Lim.

Urgency in early detection

For his part, Lotis Ramin, National President of AstraZeneca in the Philippines, said that at AstraZeneca, they recognize the urgency of early detection, diagnosis and treatment of CKD.

“We stand united with our partners to improve the healthcare ecosystem and enable solutions such as disease education and wide access to diagnostics through our advocacy programs such as the Kidney Patrol which aims to treat, know and detect CKD. We are committed to helping improve outcomes, delay progression and extend dialysis-free survival for more Filipino patients,” Ramin said.

As part of its advocacy for recognition of the burden CKD poses to Filipino patients, AstraZeneca Philippines in November 2021 shared its commitment to fight the disease through the launch of Kidney Patrol.

This is an online awareness campaign that aims to educate patients about kidney health, including preventing disease progression, dialysis and its complications. The social media-based campaign also encourages Filipinos to self-screen for risk factors and visit their doctor to recognize and detect CKD early.

Through AstraZeneca Philippines’ Kidney Patrol campaign and improved access to uACR through the company’s partnership with MedAsia, more Filipinos will be encouraged to fight the dreaded chronic kidney disease with the right CKD —Care, Know and Detect.

Picture credits: Robina Weemeijer _

About Antoine L. Cassell

Check Also

Care Quality Commission is doing ‘pioneering work’ with Deafway Preston

Naison Chaparadza The Care Quality Commission encouraged residents of deaf and hard of hearing care …